CORRELATION BETWEEN VAS OPRESSIN CONCENTRATION AND CHRONIC HEART FAILURE SEVE RITY: CHARAC TERISTICS OF PA TIENTS WITH TERMINAL AND DECOMPE NSA TED HEART FAILURE

Objective: to evaluate vasopressin (VP) concentration in patients with varying severity of chronic heart failure (CHF), intensity of clinical symptoms, and decreased level of left ventricular ejection fraction (LVEF).

 Materials and methods. In total, 120 patients (44 males, 76 females) with CHF of varying genesis (mean age 72.12 ± 10.18 years) and 30 clinically healthy individuals (18 males, 12 females) as a control group (mean age 33.4 ± 6.23 years) were examined. All patients underwent comprehensive clinical and instrumental examination in accordance with the standards for patients with CHF. The VP level was determined using ELISA. Statistical analysis was performed using the IBM SPSS Statistics v. 23 software.

Results. The patients with CHF had significantly higher blood VP levels compared to the control group (72.91 ± 53.9 pg/ml versus 6.6 ± 3.2 pg/ml respectively; p <0.01). At the same time, patients with stage III CHF had significantly lower VP levels than patients with stages IIВ and IIА (35.61 ± 21.53 pg/ml versus 71.67 ± 48.31 pg/ml and 86.73 ± 59.78 pg/ml respectively; p<0.01). A similar picture was observed for the functional classes (FC). For instance, for CHF FC II and III, the VP level was 91.93 ± 67.13 pg/ml and 77.95 ± 54.01 pg/ml respectively, while for FC IV it decreased to 50.49 ± 28.18 pg/ml (p <0.01). The VP concentration in patients who subsequently perished was significantly lower than in patients who survived (48.79 ± 26.30 pg/ml versus 79.72 ± 57.73 pg/ml; p = 0.012). Moreover, in patients with LVEF <50 %, the VP level was significantly lower than in patients with LVEF >50 % (59.43 ± 42.51 pg/ml versus 86.43 ± 62.46 pg/ml respectively; p <0.05).

Conclusion. The observed significant differences in VP in patients with stage III and IV CFH can indicate depletion of neurohumoral mediators in this patient category. However, a correlation between the VP level and the level of LVEF decrease can indicate a significant difference in the role of VP in CHF pathogenesis in patients with preserved and decreased LVEF. This observation requires further research.

1. Ziaeiana B., Fonarow G. C. The prevention of hospital readmissions in heart failure. Prog Cardiovasc Dis 2016;58(4):379–85. DOI: 10.1016/j.pcad.2015.09.004.

2. McMurray J. J., Petrie M. C., Murdoch D. R., Davie A. P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19(Suppl):9–16.

3. Polyakov D. S., Fomin I. V., Valikulova F. Yu. et al. The EPOCH–CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH–D–CHF). Zhurnal “Serdechnaya nedostatochnost’” = Russian Heart Failure Journal 2016;17(5): 299–305. (In Russ.). DOI: 10.18087/rhfj.2016.5.2239.

4. Holmes C. L., Landry D. W., Granton J. T. Science review: vasopressin and the cardiovascular system part 1 – receptor physiology. Crit Care 2003;7(6):427–34. DOI: 10.1186/cc2337.

5. Balling L., Gustafsson F. Copeptin in Heart Failure. Adv Clin Chem 2016;73:29–64. DOI: 10.1016/bs.acc.2015.10.006.

6. Goldsmith S. R., Francis G. S., Cowley A. W. et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1(6):1385–90. DOI: 10.1016/S0735-1097(83)80040-0.

7. Goldsmith S. R., Dodge-Brown D. L., Katz A. Alpha 2-adrenergic stimulation and vasopressin in congestive heart failure. J Cardiovasc Pharmacol 1989;14(3):425–9.

8. Goldsmith S. R. Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1992;19(6):1180–4. DOI: 10.1016/0735-1097(92)90321-D.

9. Decaux G., Soupart A., Vassart G. Nonpeptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371(9624):1624–32. DOI: 10.1016/S0140-6736(08)60695-9.

10. Balling L., Kistorp C., Schou M. et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 2012;18:351–8. DOI: 10.1016/j.cardfail. 2012.01.019.

11. Altura B. M. Evidence that endogenous vasopressin plays a protective role in circulatory shock. Role for reticuloendothelial system using Brattleboro rats. Experientia 1980;36(9):1080–2.

12. Chapman J. T., Hreash F., Laycock J. F., Walter S. J. The cardiovascular effects of vasopressin after haemorrhage in anaesthetized rats. J Physiol 1986;375:421–34.

13. Costa A., Toschi A., Murfuni I. et al. Local overexpression of V1a-vasopressin receptor enhances regeneration in tumor necrosis factor-induced muscle atrophy. BioMed Research International 2014;2014:235426. DOI: 10.1155/2014/235426.

14. Chang Y. Y., Yang C. H., Wang S. C. et al. Vasopressin inhibits endotoxin binding in activated macrophages. J Surg Res 2015;197(2):412–8. DOI: 10.1016/j.jss.2015.04.042.

15. Benedict C. R., Weiner D. H., Johnstone D. E. et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993; 22(4 Suppl A):146A – 153A. DOI: 10.1016/0735-1097(93)90480-O.

16. Hage C., Lund L. H., Donal E. et al. Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. Open Heart 2015;2(1):e000260. DOI: 10.1136/openhrt-2015-000260.

17. Masson S., Latini R., Carbonieri E. et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 2010;12(4):338–47. DOI: 10.1093/eurjhf/hfp206.

18. Silva Marques J., Luz-Rodrigues H., David C. et al. Biomarkers of functional class in systolic heart failure: the relevance of copeptin. Rev Port Cardiol 2012;31(11):701–10. DOI: 10.1016/j.repc.2012.09.001.

19. Neuhold S., Huelsmann M., Strunk G. et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008;52(4):266–72. DOI: 10.1016/j.jacc.2008.03.050.

20. Sivukhina E. V., Poskrebysheva A. S., Smurova Iu. V. et al. Altered hypothalamic-pituitary-adrenal axis activity in patients with chronic heart failure. Horm Metab Res 2009;41(10):778–84. DOI: 10.1055/s-0029-1224182.